O-10 ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E–mutant metastatic colorectal cancer
Eric Van Cutsem, Julien Taı̈eb, Rona Yaeger, Takayuki Yoshino, Evaristo Maiello, Elena Élez, Jeroen Dekervel, Paul J. Ross, A. Ruiz Casado, Janet Graham, Takeshi Kato, J.C. Ruffinelli, Thierry André, E. Carriere Roussel, Isabelle Klauck, M. Groc, Axel Grothey, Jean-Claude Vedovato, Josep Tabernero
Topics & Concepts
MedicineCetuximabClinical endpointColorectal cancerInternal medicineOncologyPopulationPhases of clinical researchStage (stratigraphy)Interim analysisProgression-free survivalCancerProgressive diseaseGastroenterologySurgeryClinical trialChemotherapyPaleontologyEnvironmental healthBiologyColorectal Cancer Treatments and StudiesLung Cancer Treatments and MutationsMelanoma and MAPK Pathways